4-week, Open-Label Extension Study of ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]) Treatment for Opioid-Tolerant Children and Adolescents With Breakthrough Pain.
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2014
At a glance
- Drugs Fentanyl (Primary)
- Indications Cancer pain; Pain
- Focus Adverse reactions
- Sponsors Cephalon
- 25 May 2007 Status changed from in progress to completed.
- 15 Sep 2006 Status change
- 18 Dec 2005 New trial record.